Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 240

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 240
---
,784      $              71,733      $                   8  
  Dividend received                                                                                                      –                     16,555                          –  
  Cash paid for taxes                                                                                              306,592                     12,678                          –  
  Interest on lease liability                                                                                        5,386                      2,907                     14,433  
  Non-cash financing and investing                                                                                                                                                
  Common shares issued to Xylo Technologies Ltd.                                        $                                –                    296,569      $                   –  
  Right of use assets obtained in exchange for                                                                     181,779                          –                     92,731  
  Early termination of office lease (Note 4)                                                                      ( 88,562                          –                             
  Shares obtained from Xylo Technologies Ltd.                                                                            –                          –                    455,488  
  Deferred offering costs included in non-current                                                                        –                          –                    198,173  

F-7

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  Nature                           

  Clearmind                                                                                           
  Medicine Inc. (the “ Company”) was incorporated in the province of British Columbia                 
  on July 18, 2017. The Company is a clinical pharmaceutical company currently engaged in phase       
  I/IIa clinical trials of novel psychedelic medicines that have been developed to solve widespread,  
  yet under-served, health problems. The Company’s head office is located at Suite 101                
  -1220 West 6 th Avenue, Vancouver, BC, V6H 1A5. The Company’s wholly-owned                          
  Israeli subsidiary (Clearmindmed Ltd.) functions as the research and development arm of the         
  Company.                                                                                            
 ──────────────────────────────────────────────────────────────────────────────────────────────────────

On
November 14, 2022, the Company completed a listing on the Nasdaq Capital Market (“ Nasdaq”). The Company trades under the
symbol “ CMND” on the Nasdaq and on the Frankfurt Stock Exchange, (FSE), under the symbol “ CWY”. The Company was
listed on the Canadian Securities Exchange (“ CSE”) in Toronto until March 14, 2024. Following approval for a voluntary delisting,
the Company no longer trades on the CSE but remains a reporting issuer in Canada.

On
April 6, 2023, the Company completed an underwritten public offering for aggregate gross proceeds of $ 3.5 2